艾美捷科技代理FormuMax品牌。

FormuMax Scientific公司专注于药物递送领域，基于脂质体和其他新型纳米递送技术，开发了一些列产品。包括：

Mikosome™（外泌体模拟脂质体）

脂质纳米粒子（LNPs）

Clophosome®-氯膦酸脂质体

Doxoves®-脂质体盐酸阿霉素

用于药物装载的脂质体

阳离子脂质体

Trans-Hi™DNA转染试剂

荧光脂质体

预成型脂质体

载药脂质体

特色产品：

聚乙二醇化免疫球蛋白™（生物素化）脂质体，荧光（DiR）标记的Mikosome™（2毫升），荧光（DiO）标记的Mikosome™ (2mL)等等

艾美捷科技代理Lifeome品牌全系列产品

Lifeome公司致力于基因组学、转录组学及蛋白质组学领域的产品研发、生产与市场化，提供全方位的研究产品与服务体系。Lifeome核心产品包括生长因子、抗体、病毒蛋白、重组蛋白，基因工程克隆载体等。

▍Lifeome公司的服务

● 定制抗体开发服务：多克隆与单克隆抗体解决方案，应用于蛋白定量检测、细胞/组织定位分析（活体或固定样本），由政府认证实验室提供全流程生产服务；

● 高端多肽合成解决方案：由平均从业5年以上的技术专家操作顶级合成系统，覆盖从基础科研到工业级生产需求；

● 蛋白质表达与纯化：其培养简便、产量高，能快速获得免疫原。

▍Lifeome部分产品列表

Allele Biotechnology位于美国圣地亚哥市，主要专注于对生物过程的机制进行探索，以开发生物医学及治疗相关的技术和产品。以各个物种的iPS细胞、人类cGMP iPS细胞及衍生的细胞为材料，Allele Biotechnology利用专利性的非整合细胞编辑方法，开发了出了细胞治疗和药物筛选的技术。Allele Biotechnology具有深厚的基因组修饰和细胞荧光报告因子的经验，为客户提供优异的细胞检测解决方案。Allele Biotechnology还提供荧光蛋白、高效荧光素酶底物、基因分型试剂盒、骆驼抗体等产品；此外还在RNA干扰领域尤其独特的专利。

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to develop cell therapy and enable drug discovery through the use of human and non-human primate iPS cells, cGMP-grade human iPS cells and their derivatives. With additional expertise in genome modification and unique cell-based fluorescence sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of advanced research tools including superior fluorescent proteins, highly efficient luciferase assay substrates, genotyping kits, and camelid antibodies that have been validated for co-immunoprecipitation, histology, and flow cytometry. The Company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.